Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and United Therapeutics (UTHR) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank favors stocks with stron ...

Core Viewpoint - Catalyst Pharmaceuticals is being presented at a Barclays event, highlighting its significance in the life sciences sector [1] Company Overview - Rich Daly, the Chief Executive Officer of Catalyst Pharmaceuticals, is participating in the presentation, indicating the company's leadership engagement [1] - The presentation is part of a broader discussion on the life sciences industry, specifically focusing on specialty pharmaceuticals and animal health [1]

分组1 - Catalyst Pharmaceutical (CPRX) shares have increased by 1.7% over the past four weeks, closing at $24.32, with a mean price target of $34.86 indicating a potential upside of 43.3% [1] - The average price targets from analysts range from a low of $32.00 to a high of $38.00, with a standard deviation of $1.95, suggesting a strong agreement among analysts regarding the stock's potential movement [2] - Analysts have shown strong optimism regarding CPRX's earnings prospects, with a 13% increase in the Zacks Consensus Estimate for the current year, indicating a positive trend in earnings estimate revisions [12][11] 分组2 - CPRX holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, which supports the stock's potential upside [13] - While the consensus price target may not be a reliable indicator of the exact price movement, it does provide a useful guide for understanding the direction of price movement [14]

Company Overview - American Well Corporation (AMWL) is a member of the Medical sector, which includes 926 individual stocks and currently holds a Zacks Sector Rank of 9 [2] - AMWL is part of the Medical Info Systems industry, which consists of 42 individual stocks and is ranked 138 in the Zacks Industry Rank [6] Performance Analysis - AMWL has gained approximately 14.3% year-to-date, outperforming the average loss of about 1% in the Medical group [4] - Over the past three months, the Zacks Consensus Estimate for AMWL's full-year earnings has increased by 36.6%, indicating improved analyst sentiment and a stronger earnings outlook [4] - In comparison, Catalyst Pharmaceutical (CPRX) has returned 4.2% year-to-date and has a Zacks Rank of 1 (Strong Buy) with a 13% increase in the consensus EPS estimate over the past three months [5] Industry Comparison - The Medical Info Systems industry has experienced an average loss of 18% year-to-date, highlighting AMWL's superior performance within its industry [6] - The Medical - Drugs industry, to which Catalyst Pharmaceutical belongs, is ranked 93 and has moved -2.7% so far this year [6] Investment Outlook - Investors interested in Medical stocks should continue to monitor American Well Corporation and Catalyst Pharmaceutical for their solid performance [7]

Core Insights - Catalyst Pharmaceuticals is showcasing real-world findings in Duchenne muscular dystrophy (DMD) at the 2026 MDA Clinical & Scientific Conference, emphasizing their commitment to advancing research and patient care [1][2] Poster Presentations - The company will present multiple posters focusing on the real-world analysis of vamorolone, a novel corticosteroid, in DMD patients, including studies on cardiac medication use and glucocorticoid treatment duration [3][4] - Specific poster titles include "Real-world analysis of concomitant cardiac medication use with the novel corticosteroid vamorolone in patients with Duchenne muscular dystrophy" and "Association Between Glucocorticoid Treatment Duration and Health Care Resource Utilization in Duchenne Muscular Dystrophy" [3][4] Symposium - Catalyst Pharmaceuticals is sponsoring an MDA Industry Forum in conjunction with Santhera Pharmaceuticals, which will feature insights from clinical leaders on advancing understanding of DMD [5][6] Company Overview - Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, with a strong commitment to patient care and accessibility [6] - The company has been recognized by Forbes as one of America's Most Successful Companies for three consecutive years (2023-2025) and listed on the 2025 Deloitte Technology Fast 500™ as one of North America's Fastest-Growing Companies [6]

Core Viewpoint - Catalyst Pharmaceutical (CPRX) has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Revisions - The Zacks Consensus Estimate for Catalyst for the fiscal year ending December 2026 is projected at $2.82 per share, remaining unchanged from the previous year [8]. - Over the past three months, analysts have increased their earnings estimates for Catalyst by 13% [8]. Zacks Rating System - The Zacks rating system evaluates stocks based on changes in earnings estimates, categorizing them into five groups from Zacks Rank 1 (Strong Buy) to Zacks Rank 5 (Strong Sell) [7]. - Zacks Rank 1 stocks have historically generated an average annual return of +25% since 1988, showcasing the effectiveness of the rating system [7]. Market Implications - The upgrade to Zacks Rank 1 places Catalyst in the top 5% of Zacks-covered stocks, suggesting a strong potential for price appreciation in the near term due to favorable earnings estimate revisions [10].

Group 1 - Catalyst Pharmaceuticals, Inc. reported record total revenues of $589.0 million for the full year 2025, reflecting a 19.8% year-over-year growth [1] - Fiscal Q4 2025 revenues reached $152.6 million, driven by an 18.3% growth in FIRDAPSE® and a significant 67.5% growth in AGAMREE® [1] - The company expects total revenues for the full year 2026 to be between $615 million and $645 million, indicating confidence in the FIRDAPSE and AGAMREE franchises [2] Group 2 - The strong performance in fiscal Q4 2025 is attributed to ongoing organic product growth and the accelerating market uptake of AGAMREE [2] - The solid full-year 2025 performance was supported by sustained organic momentum and operational discipline [2] - Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing novel medicines for rare diseases [3]

Core Insights - The company is presenting its preliminary results for the full year 2025 and providing a strategy update for 2026 [1] - The presentation will include an overview of main achievements, strategic priorities, and key financial targets for 2026 [1] Presentation Structure - The CEO, Matteo Del Fante, will lead the presentation with an overview of achievements and strategic priorities [2] - The CFO, Camillo Greco, will provide a detailed analysis of the financials [1] - A Q&A session will follow the closing remarks from the CEO, with an invitation for further inquiries to the Investor Relations team [1]

Core Insights - Catalyst Pharmaceuticals (CPRX) reported adjusted earnings of 68 cents per share for Q4 2025, exceeding the Zacks Consensus Estimate of 42 cents and slightly down from 70 cents in the same quarter last year [1] - Total revenues reached $152.6 million, an 8% year-over-year increase, surpassing the Zacks Consensus Estimate of $140 million [1] Revenue Breakdown - The primary revenue sources included Firdapse, Agamree, and Fycompa, with Firdapse sales at $97.6 million, an 18% increase year-over-year, and Agamree generating $35.3 million, up 68% year-over-year [2][3][5] - Fycompa generated $19.6 million in net product revenues, a significant decline year-over-year due to the introduction of generic competitors [8] Financial Performance - For the full year 2025, Catalyst Pharmaceuticals recorded total revenues of $589 million, a 20% increase year-over-year, and adjusted earnings per share of $2.72, surpassing the Zacks Consensus Estimate of $2.46 [12] - The company expects 2026 total revenues between $615 million and $645 million, driven by growth in Firdapse and Agamree sales [13] Future Guidance - Firdapse revenues are projected between $435 million and $450 million, while Agamree revenues are anticipated between $140 million and $150 million for 2026 [13] - Fycompa revenues are expected to be between $40 million and $45 million, despite the loss of patent exclusivity [14] Research and Development - Research and development expenses for the reported quarter were $1.8 million, down 52% year-over-year, while selling, general, and administrative expenses totaled $53.4 million, up 21% year-over-year [9] Strategic Developments - Catalyst Pharmaceuticals acquired exclusive rights to manufacture and supply Agamree in 2023, which was approved for treating Duchenne Muscular Dystrophy [4] - The company is currently evaluating Agamree in the SUMMIT study to assess its long-term clinical safety profile [16]

Group 1 - Catalyst Pharmaceutical (CPRX) reported revenue of $152.61 million for the quarter ended December 2025, reflecting a 7.6% increase year-over-year and a 9% surprise over the Zacks Consensus Estimate of $140.02 million [1] - The earnings per share (EPS) for the quarter was $0.68, down from $0.70 in the same quarter last year, with a significant EPS surprise of +60.95% compared to the consensus estimate of $0.42 [1] - The stock has returned +2.7% over the past month, outperforming the Zacks S&P 500 composite's +0.6% change, and currently holds a Zacks Rank 3 (Hold) [3] Group 2 - Product revenue net for the quarter was $152.5 million, exceeding the average estimate of $140.01 million from four analysts, marking a year-over-year change of +7.5% [4] - FIRDAPSE generated $97.62 million in revenue, surpassing the estimated $96.43 million, representing an 18.3% increase year-over-year [4] - AGAMREE revenue reached $35.3 million, exceeding the average estimate of $31.3 million, with a year-over-year change of +67.5% [4] - FYCOMPA reported revenue of $19.58 million, compared to the average estimate of $12.28 million, indicating a year-over-year decline of -48.8% [4] - License and other revenues were $0.11 million, significantly higher than the estimated $0.03 million, reflecting a remarkable +909.1% change year-over-year [4]